Eculizumab
Pharmaceutical drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Eculizumab?
Summarize this article for a 10 year old
Eculizumab, sold under the brand name Soliris among others, is a recombinant humanized monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica.[8][9] In people with paroxysmal nocturnal hemoglobinuria, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death.[11] Eculizumab was the first medication approved for each of its uses, and its approval was granted based on small trials.[12][13][14][15] It is given by intravenous infusion.[8] It is a humanized monoclonal antibody functioning as a terminal complement inhibitor.[13] It binds to the complement C5 protein and inhibits activation of the complement system, a part of the body's immune system.[16] This binding prevents the breakdown of red blood cells in the bloodstream (intravascular hemolysis) in people with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.[16]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | Complement protein C5 |
Clinical data | |
Trade names | Soliris |
Biosimilars | Bekemv,[1] Elizaria,[2] Bkemv,[3] eculizumab-aagh, eculizumab-aeeb,[3] Epysqli[4] |
AHFS/Drugs.com | Monograph |
MedlinePlus | a612024 |
License data |
|
Pregnancy category |
|
Routes of administration | Intravenous |
Drug class | Complement inhibitor |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 8 to 15 days (mean 11 days) |
Identifiers | |
CAS Number | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Molar mass | 148 kg/mol |
NY (what is this?) (verify) |
The most frequently reported adverse reactions for people with paroxysmal nocturnal hemoglobinuria include headache, nasopharyngitis (common cold), back pain and nausea[16] The most frequently reported adverse reactions for people with atypical hemolytic uremic syndrome include headache, diarrhea, hypertension, upper respiratory infection, abdominal pain, vomiting, nasopharyngitis, anemia, cough, swelling of lower legs or hands, nausea, urinary tract infections and fever[16]
Eculizumab (Soliris) is developed, manufactured, and marketed by Alexion Pharmaceuticals.[17]: 6